Leading Chinese KOL puts microkeratomes through their paces

Article

Professor Ye-Guo Chen, one of the top five key opinion leaders in Chinese refractive surgery has demonstrated a drastic improvement in flap thickness and planarity when using the One Use-Plus SBK microkeratome, defined as 'Sub Bowman's Keratomileusis. '

Professor Ye-Guo Chen, one of the top five key opinion leaders in Chinese refractive surgery has demonstrated a drastic improvement in flap thickness and planarity when using the One Use-Plus SBK microkeratome, defined as 'Sub Bowman's Keratomileusis. '

In the study, which is published in the Journal of Refractive Surgery(June issue) the investigators concluded that the One Use-Plus and M2 microkeratomes have similar safety and efficacy. However, the One Use-Plus was not able to realize a fully planar-shaped flap.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.